US court upholds Merck's Zetia/Vytorin patent, keeping Mylan out until 2017
This article was originally published in Scrip
Executive Summary
A US federal judge has ruled in two jointly related patent infringement suits against Mylan that a patent on Merck & Co's hypolipaemic Zetia (ezetimibe) and related product Vytorin (ezetimibe plus simvastatin) is valid and issued an injunction blocking the approval of generic versions by Mylan until the patent at issue expires 25 April 2017.